眾生藥業(002317.SZ):複方丹蔘片等4項藥品擬中選廣東聯盟中成藥集中帶量採購
格隆匯4月13日丨眾生藥業(002317.SZ)公佈,2022年4月8日,廣東省藥品交易中心對清開靈等中成藥集中帶量採購擬中選/備選結果予以公示,於2022年4月12日結束公示。本次集中帶量採購系廣東省聯合山西、河南、海南、寧夏、青海組成採購聯盟,對國家基本醫保藥品目錄內用量大、採購金額高的132箇中成藥開展的省際聯盟集中帶量採購。
公司和公司全資子公司華南藥業積極參與本次集中帶量採購工作。前述擬中選/備選結果公示顯示,公司產品複方丹蔘片、複方血栓通膠囊和華南藥業產品複方血栓通軟膠囊、腦栓通膠囊擬中選。
公司上述4個產品擬在本次集中帶量採購中選,有助於公司在聯盟六省繼續保持市場競爭優勢,併為持續擴大市場份額奠定基礎。公司核心產品複方血栓通多劑型擬中選,鞏固了公司通用名產品的市場領先地位。華南藥業獨家產品腦栓通膠囊擬中選,為公司在腦血管病細分市場中強化競爭優勢提供助力,有望成為腦卒中治療領域的重要中成藥品種。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.